Table 1. Baseline characteristics in 34 patients undergoing MitraClip procedure, of whom 9 experienced MACE.

	Events	Non-Events	p-value
Number	9	25	n/a
Age [years]	79.6 (8.6)	79.4 (6.7)	0.95
Hypertension [%]	78	80	0.73
Hyperlipidemia [%]	67	64	0.96
Type 2 Diabetes [%]	33	24	0.92
Current or former smoker [%]	33	20	0.77
Male Sex [%]	56	52	0.84
Known CHD [%]	89	84	0.85
NYHA Classification [%]			0.86
III	33	36
III-IV	33	24
IV	33	40
Degree of insufficiency (1–3) Median	3	3	0.96
Left-ventricular ejection fraction [%]			0.30
Above 50%	33	68
Between 30%-50%	56	28
Below 30%	11	4
Atrial Fibrillation [%]	67	48	0.57
Etiology of Mitral Insufficiency [%]			0.12
Degenerative	56	88
Functional	44	12
Logistic Euro Score [%]			0.15
Mean	27.8 (19.4)	16.9 (16.5)
Median	26.8 [12.3; 41.7]	11.9 [6.8; 21.6]
STS-Score [%]			0.06
Mean Risk for Mortality	17.1 (11.0)	11.1 (7.3)
Median Risk for Mortality	14.3 [12.0; 22.6]	9.9 [5.8; 12.7]
NT-proBNP [pg/mL]			0.0004
Mean	12,705 (10,702)	2,168 (1,602)
Median	11,251 [3619; 19137]	1,974 [1051; 2940]
MR-proANP [pmol/L]			0.0001
Mean	757.1 (298.2)	330.37 (127.66)
Median	755.6 [570.2; 800.6]	318.30 [261.4; 387.2]
Hs-TnT [ng/L]			0.0047
Mean	267.5 (534.8)	36.55 (33.3)
Median	92.6 [38.0; 155.5]	25.20 [16.4; 48.7]
Hs-CRP [mg/L]			0.0334
Mean	37.6 (66.9)	6.8 (7.6)
Median	14.6 [4.3; 32.0]	5.5 [1.5; 8.3]
Cystatin C [mg/L]			0.0112
Mean	2.2 (0.7)	1.5 (0.6)
Median	2.1 [1.7; 2.6]	1.4 [1.2; 1.7]
Galectin-3 [ng/mL]			0.0007
Mean	37.4 (14.0)	19.2 (9.7)
Median	34.8 [26.1; 48.1]	16.6 [12.9; 20.6]
SST-2 [ng/mL]			0.0025
Mean	119.9 (116.4)	37.3 (20.6)
Median	75.1 [52.7; 134.8]	29.4 [24.9; 43.6]